Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atidarsagene autotemcel - Orchard Therapeutics

Next Previous
Search
Drug Profile

Atidarsagene autotemcel - Orchard Therapeutics

Alternative Names: ARSA gene therapy - GSK/Fondazione Telethon/Ospedale San Raffaele; ARSA transduced autologous CD34+ stem cells - GSK/Fondazione Telethon/Ospedale San Raffaele; Arylsulfatase A gene therapy -GSK/Fondazione Telethon/Ospedale San Raffaele; Ex vivo stem cell gene therapy - GSK/Fondazione Telethon/Ospedale San Raffaele; GSK 2696274; Lenmeldy; Libmeldy; OTL-200

Latest Information Update: 19 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fondazione Telethon; GlaxoSmithKline; Ospedale San Raffaele
  • Developer Orchard Therapeutics; The San Raffaele Telethon Institute for Gene Therapy (JV)
  • Class Gene therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Arylsulfatase replacements; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metachromatic leukodystrophy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Metachromatic leukodystrophy

Most Recent Events

  • 12 Feb 2025 Launched for Metachromatic leukodystrophy (In children) in USA (IV) prior to February 2025
  • 07 Oct 2024 Orchard Therapeutics enters into distribution agreement with ErKim for Atidarsagene autotemcel for Metachromatic leukodystrophy in Turkey, Russia, Ukraine and the Commonwealth of Independent States
  • 20 Mar 2024 US FDA plans to launch Lenmeldy™ for the treatment of Metachromatic leukodystrophy (In children) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top